5 Top Weekly NASDAQ Biotech Stocks: vTv Increases 163 Percent
vTv Therapeutics, Teligent, EyePoint Pharmaceuticals, Catalyst Biosciences and Eleven Biotherapeutics were last week’s top gainers.
Your trusted source for investing success
Your trusted source for investing success
vTv Therapeutics, Teligent, EyePoint Pharmaceuticals, Catalyst Biosciences and Eleven Biotherapeutics were last week’s top gainers.
The Investing News Network rounds up some of the biggest company and market news in the cannabis market for the past trading week.
In case you missed it, here is this week’s big news roundup in the Life Science sector.
In case you missed it, here is this week’s big news roundup in Technology.
In case you missed it, here is this week’s cannabis big news roundup.
Abeona Therapeutics (NASDAQ:ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel cell and gene therapies for life-threatening rare genetic diseases, announced today that the European Medicines Agency (EMA) Committee for Orphan Medicinal Products has granted Orphan Drug Designation (EMA/OD/013/18) for Abeona’s gene therapy program ABO-202 for the treatment of
Australian stem cell and regenerative medicine company, Cynata Therapeutics Limited (ASX:CYP) announced that it has completed the filing of a patent application with IP Australia that would cover the therapeutic use of its Cymerus™ stem cell technology in the treatment of adverse reactions associated with chimeric antigen receptor T-cell (CAR-T)
Clementia Pharmaceuticals (NASDAQ:CMTA), a clinical-stage company innovating new treatments for people with ultra-rare bone disorders and other diseases, today announced the start of the MO-Ped Trial, its Phase 2 study evaluating the safety and efficacy of palovarotene for the treatment of pediatric patients with multiple osteochondromas (MO), also known as multiple
Advanced Biomedical Technologies (OTCQB:ABMT), a developer and manufacturer of orthopaedic internal fixation devices, announced today that it has received approval from the China Food and Drug Administration for its polymer orthopaedic internal fixation screws.
As quoted in the press release:
Company CEO Ms Hui Wang said, “Today is a momentous day for
With Q1 2018 officially in the books, here the Investing News Network takes a look back at what some of the biggest genetics news was so far this year.
CTD Holdings (OTCQB: CTDH), a clinical stage biotechnology company that develops cyclodextrin-based products for the treatment of disease with unmet medical need, announced today that the company has finalized a cooperative research agreement with Kerwin Research Center, LLC to explore the use of cyclodextrins in the treatment of Alzheimer’s disease.
As quoted
OpGen (NASDAQ:OPGN) OpGen announced today that it successfully completed a prospective clinical trial evaluating the impact of using rapid diagnostic testing for identification and treatment of bacteremia and fungemia in hospital intensive care units in Colombia. The study showed significant improvement in survival and reductions in antibiotic usage for patients
Krystal Biotech (NASDAQ:KRYS), a gene therapy company dedicated to developing and commercializing novel treatments for patients suffering from dermatological diseases, today announces that KB103, a gene therapy candidate for dystrophic epidermolysis bullosa (“DEB”), was granted Orphan Medicinal Product Designation (OMPD) from the European Medicines Agency (EMA). KB103 represents the first
Summit Therapeutics (NASDAQ:SMMT) announces the completion of ezutromid dosing in patients with Duchenne muscular dystrophy (‘DMD’) for the full 48-week PhaseOut DMD clinical trial. Top-line data from the full trial continue to be expected in the third quarter of 2018.
As quoted in the press release:
“We believe the early improvements seen
Adamas Pharmaceuticals (Nasdaq:ADMS) today announced positive data from EASE LID 2, the company’s two-year Phase 3 open-label study of GOCOVRI™ (amantadine) extended release capsules, the first and only medicine approved by the U.S. Food and Drug Administration (FDA) for the treatment of dyskinesia in patients with Parkinson’s disease receiving levodopa-based
Flexion Therapeutics (Nasdaq:FLXN) today announced that the key results from the previously completed pivotal Phase 3 study evaluating ZILRETTA (triamcinolone acetonide extended-release injectable suspension) have been published in the print and online edition of the Journal of Bone and Joint Surgery (Vol 100 (8) pp 666 – 677). ZILRETTA was approved by
Alliance Growers Corp. (CSE:ACG) (“Alliance Growers” or the “Company”) is pleased to report that it has executed the exclusive agreement to acquire the licensed producer applicant, BiocannaTech Inc. (“BiocannaTech”), to become a licensed producer under Health Canada’s access to cannabis for medical purposes regulations (“ACMPR”) in Quebec.
By Pia Rivera
Kalytera Therapeutics, Inc. (TSXV:KALY. OTCQB:KALTF) announced that the U.S. Patent and Trademark Office (“USPTO”) issued U.S. Patent No. 9,889,100 B2 with claims covering the use of cannabidiol (“CBD”) for the treatment of severe and refractory graft versus host disease.
Medigus and HC Marbella International Hospital announced the first successful MUSE procedure for GERD treatment on a single patient in Spain.
Opiant Pharmaceuticals (NASDAQ:OPNT), a specialty pharmaceutical company developing pharmacological treatments for addictions, today announced that it has been awarded a grant of approximately $7.4 million from the National Institutes of Health’s National Institute on Drug Abuse (NIDA) for the development of OPNT003 (intranasal nalmefene), a long-lasting opioid antagonist for the
